Vor Bio (Nasdaq: VOR) has secured approximately $55.6 million in private placement financing to advance its innovative cell and genome engineering pipeline for blood cancers. The financing round, announced December 27, 2024, was led by new investor Reid Hoffman and included participation from the company's largest stockholder, RA Capital Management.
The Cambridge-based clinical-stage biotechnology company will issue 55,871,260 shares of common stock along with warrants to purchase an additional 69,839,075 shares at $0.838 per share. If the warrants are fully exercised, Vor Bio could receive up to an additional $58.5 million in proceeds.
Strategic Investment Strengthens Leadership
As part of the investment agreement, both Reid Hoffman and RA Capital Management will receive one board seat and one board observer seat, strengthening the company's strategic oversight. The combined expertise is expected to support Vor Bio's mission to revolutionize blood cancer treatment through cell and genome engineering.
"Acute myeloid leukemia ranks among the deadliest cancers in the world, and a treatment for it has been sought for decades," said Reid Hoffman. "Vor's trem-cel therapy, which uses CRISPR/cas9 to edit the bone marrow of patients, represents a new potential breakthrough. Early data released by Vor suggest a potent effect, which now must be confirmed by future trials."
Pipeline Progress and Clinical Milestones
The funding extends Vor Bio's cash runway through several important clinical milestones. The company plans to announce:
- Updated clinical data from the Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025
- Updated clinical data from the Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025
The company's innovative approach focuses on engineering hematopoietic stem cells to enable targeted therapies post-transplant, potentially offering new hope for patients with blood cancers who have limited treatment options.
Financial Terms and Use of Proceeds
The private placement was priced at $0.99425 per share and accompanying warrants, based partly on the last reported sale price of the common stock on the Nasdaq Global Select Market. Stifel served as the sole placement agent for the transaction.
Vor Bio intends to use the net proceeds to fund clinical and preclinical development of its pipeline candidates and for general corporate purposes. The transaction is expected to close on December 30, 2024, subject to customary closing conditions.
